Combining nitric oxide and plasma
technology to transform health


Overcoming drawbacks of topical
and systemic delivery

 

Origin has developed a patented, portable device with a handheld, computer-guided system that generates nitric oxide (NO) from ambient room air within a defined plasma stream. The plasma-generated NO is safely delivered directly to the target treatment area. The plasma-generated NO interacts with human tissue to mediate disease effects. Origin's™ proprietary technology is based on Nobel Prize-winning discoveries in Physics (1970) and Medicine (1998).

Plasma-generated NO that is created at the point of care is designed to prolong the time that NO remains on the affected area while avoiding the risks associated with other modes of administration.1

 

Origin plasma solution for wound healing

Although there is enormous potential for plasma-generated NO in many areas of medicine, Origin is first focusing on the healing of chronic wounds. This is a therapeutic area in which Origin can make an important difference in a large number of patients in a short time. NO plays multiple important roles in wound healing. Origin's research in plasma-generated NO is demonstrating proof of concept.


Learn more about specific applications in the Clinical Pipeline.



Clinical Pipeline

Diabetic Foot Ulcers (DFU)

Origin’s initial focus is on chronic skin wounds, specifically DFUs, because they are such a growing concern:


Troublesome incidence of DFUs

  • 15%-25% of people with diabetes will develop a foot ulcer2
  • Only 62% of DFU wounds are healed after primary treatment, and healing can take 5 months or more3

DFUs increasing in number, in line with the growth of diabetes in the community

  • 29.1 million people in the US (9.3% of the population) living with diabetes4
  • 552 million worldwide are predicted to be living with diabetes by the year 20305

High mortality rate and risk of complications

  • 66% of DFUs recur, increasing the risk of amputation6
  • DFU precedes 85% of diabetes-associated amputations7
  • Estimated 5-year mortality rates after DFU is 45%-55%8
  • Mortality rate increases to 50%-68% following amputation9

High economic burden

  • Approximately 6% of Medicare expenditure annually4
  • Cost of DFU treatment was approximately $9-$13 billion in the US in 20154
  • Incremental DFU cost per episode ranges from $11,710 for Medicare to $15,890 for private insurance10

The underlying pathophysiology of DFUs is complex, and involves a deficiency of NO. Origin's approach is intended to restore NO in order to reduce the use of advanced therapies and to improve the quality of healing, improve circulation, and reduce risk of amputation.

Top

References: 1. Heinlin J, et al. Plasma medicine: possible applications in dermatology. J Dtsch Dermatol Ges. 2010;8(12):968-976. 2. Stang D, et al. Making prevention pay. Diabetic Foot J. 2015;18(1):20-24. 3. Jeffcoate WJ, et al. Diabetic foot ulcers. Lancet. 2003;361(9368):1545-1551. 4. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2014 http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. 5. International Diabetes Federation. http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition. Accessed October 29, 2015. 6. Hunt D. Diabetes: foot ulcers and amputations. Am Fam Physician. 2009;80:789-790. 7. Robbins JM, et al. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration?J AM Podiatr Med Assoc. 2008;98:489-493. 8. Deshpande AD, et al. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-1264. 9. Wounds International. Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. London: Wounds International. 2013. 10. Rice et al. Burden of Diabetic Foot Ulcers for Medicare and Private Insurance. Diabetes Care. 2013. http://care.diabetesjournals.org/content/37/3/651.full.pdf. Accessed March 15, 2016.

Clinical Trials in Diabetic Foot Ulcers (DFU)


We welcome applications from physicians, investigators, and clinical researchers.


If you are interested in learning more about our clinical trials, including how to become an investigator or how to enroll a patient, or call 609-250-6006.


If you are a patient interested in participating in a clinical trial.


For additional information on all completed, active, and planned Origin-sponsored clinical trials, visit: ClinicalTrials.gov

Top